Ignite Creation Date:
2025-12-25 @ 12:27 AM
Ignite Modification Date:
2026-01-06 @ 4:08 AM
Study NCT ID:
NCT00408967
Status:
WITHDRAWN
Last Update Posted:
2017-08-18
First Post:
2006-12-06
Is NOT Gene Therapy:
True
Has Adverse Events:
False
Brief Title:
Determine if Either of 2 Doses of Study Drug Given With a Low-dose of Cyclophosphamide After a Complete or Partial Response to a Platinum-based Second-line Therapy in Women With Recurrent Ovarian Carcinoma Results in a Longer Time to Progression When Compared to the First Time to Progression.
Sponsor:
EMD Serono
Organization:
Organization Data
Organization:
Class:
INDUSTRY
Study ID:
EMR 62206-016
Study Type:
None
Study Domain:
None
Study Link:
None
Lead Sponsor:
Lead Sponsor Class:
INDUSTRY
Responsible Party:
Responsible Party Title:
Responsible Party Type:
SPONSOR
Responsible Party Affiliation:
Old Name:
None
Old Organization:
None